Dr. John Leonard excels in hematology research and patient care

John Leonard, MD, from Weill Cornell Medicine in New York, is gaining recognition for his contributions to hematologic research and patient care. He is well-known for creating the "Leonard List," which highlights upcoming research that will be presented at the annual American Society of Hematology (ASH) meetings in December. His insights have gained traction on social media, with one of his tweets about research on a specific type of lymphoma garnering over 16,000 views. Since 2018, Leonard has also discussed major research developments in an annual episode of Weill Cornell’s Cancer Cast podcast. As a senior associate dean, he aims to bridge research findings with industry applications for wider community benefits. Leonard has a strong publication record. In 2024, he authored 11 articles in peer-reviewed journals, focusing on advancements in treatments for follicular lymphoma. He expressed optimism about new therapies, suggesting they might lead to long-lasting remissions akin to a cure, though he emphasized that chemotherapy remains a staple treatment. He began his oncology career in the mid-1990s when new treatments like monoclonal antibodies began entering the market. Leonard continues to find ways to improve standard treatments alongside a keen interest in new experimental drugs. Beyond his research, Leonard is praised for his bedside manner. He often connects with patients by discussing sports or personal interests, building rapport beyond medical discussions. For instance, he shares a love of baseball and finds common ground with patients through these interactions. Leonard's patient care has earned him awards and recognition. One patient, concert pianist Horacio Gutiérrez, expressed gratitude for how Leonard tailored treatment to avoid side effects that could hinder his musical career. Gutiérrez learned that many patients felt equally valued in Leonard's care, highlighting his ability to make everyone feel special. Leonard’s career reflects both his commitment to advancing cancer treatment and his dedication to the well-being of his patients.